⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22536342 | 1.00 | — | — | |
| SCHEMBL129783 | 0.97 | — | — | |
| SCHEMBL12377989 | 0.97 | — | — | |
| SCHEMBL19538519 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3485079 | 0.94 | — | — | |
| Benzene SCHEMBL28251032 | 0.89 | THRB (0.32) | — | |
| SCHEMBL320583 | 0.88 | — | — | |
| SCHEMBL7173607 | 0.88 | — | — | |
| SCHEMBL184525 | 0.88 | — | — | |
| Potassium SCHEMBL30207800 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | claimed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | claimed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | claimed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| CN-111542526-B | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4028396-A1 | PROCESS FOR THE PREPARATION OF A MEDICAMENT CONTAINING AN OXEPANE RING | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| CN-114601930-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-114404595-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021050654-A1 | PROCESS FOR THE PREPARATION OF A MEDICAMENT CONTAINING AN OXEPANE RING. | GENENTECH, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| CN-105612159-A | Crystal of diazabicyclooctane derivative and process for producing the same | MEIJI SEIKA PHARMA CO LTD | 2016-05-25 | — | — | CN | disclosed |
| US-20120238579-A1 | New Compounds 806 | BESIDKI YEVGENI (SE) | 2012-09-20 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| EP-1770091-A1 | CGRP-antagonists, process for their preparation as well as their use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |